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Abstract
Introduction:  Saliva  plays  a  key  role  in  the  homeostasis  of  the  digestive  tract,  through  its  inor-
ganic components  and  its  protein  growth  factors.  Sjögren’s  syndrome  patients  have  a  higher
prevalence  of  gastroesophageal  reﬂux  disease  and  laryngopharyngeal  reﬂux.  Decreased  salivary
transforming  growth  factor  alpha  levels  were  observed  in  dyspeptic  patients,  but  there  have
been no  studies  in  patients  with  Sjögren’s  syndrome  and  laryngopharyngeal  reﬂux.
Objective:  To  compare  the  salivary  transforming  growth  factor  alpha  levels  of  patients  with
Sjögren’s syndrome  and  laryngopharyngeal  reﬂux  to  those  of  healthy  controls.
Methods:  This  is  a  prospective  controlled  study.  Twelve  patients  with  Sjögren’s  syndrome  and
laryngopharyngeal  reﬂux  and  11  controls  were  prospectively  evaluated.  Spontaneous  and  stim-
ulated saliva  samples  were  obtained  to  establish  salivary  transforming  growth  factor  alpha
concentrations.
Results: The  salivary  transforming  growth  factor  alpha  levels  of  patients  were  signiﬁcantly
higher than  those  of  healthy  controls.  Five  patients  with  laryngopharyngeal  reﬂux  also  had
erosive esophagitis;  their  salivary  transforming  growth  factor  alpha  levels  were  comparable  to
controls.
 Please cite this article as: Corvo MA, Eckley CA, Rizzo LV, Sardinha LR, Rodriguez TN, Bussoloti Filho I. Salivary transforming growth
actor alpha in patients with Sjögren’s syndrome and reﬂux laryngitis. Braz J Otorhinolaryngol. 2014;80:462--9.
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Conclusion:  Salivary  transforming  growth  factor  alpha  level  was  signiﬁcantly  higher  in  patients
with Sjögren’s  syndrome  and  laryngopharyngeal  reﬂux  when  compared  to  the  control  group.
© 2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Estudo  da  concentrac¸ão salivar  do  fator  transformador  de  crescimento  alfa  em
indivíduos  com  Síndrome  de  Sjögren  e  reﬂuxo  laringofaríngeo
Resumo
Introduc¸ão: A  saliva  exerce  inﬂuência  primordial  na  homeostase  do  sistema  digestório,  pelos
seus componentes  inorgânicos  e  pelos  fatores  de  crescimento.  Indivíduos  com  síndrome  de
Sjögren (SS)  apresentam  maior  incidência  da  doenc¸a  do  reﬂuxo  gastroesofágico  (DRGE)  e  do
reﬂuxo laringofaríngeo  (RLF).  Concentrac¸ões  salivares  diminuídas  do  fator  transformador  de
crescimento-alfa  (TGF-)  foram  observadas  em  doentes  dispépticos,  porém  não  há  estudos  em
populac¸ões com  SS  e  RLF.
Objetivo:  Comparar  concentrac¸ões  salivares  do  TGF-;  de  indivíduos  com  SS  e  RLF  a  de  con-
troles saudáveis.
Método:  Trata-se  de  um  estudo  prospectivo  controlado.  Doze  pacientes  com  SS  e  RLF  e  11
indivíduos controles  saudáveis  tiveram  amostras  salivares  espontâneas  e  estimuladas  coletadas
para estabelecer  concentrac¸ão  de  TGF-.
Resultados:  A  concentrac¸ão  salivar  de  TGF-;  foi  estatisticamente  maior  no  grupo  estudo  para
ambas amostras.  Este  aumento  foi  conﬁrmado  nos  sete  indivíduos  do  grupo  estudo  que  não  apre-
sentavam  esofagite  erosiva  quando  comparados  ao  grupo  controle,  porém  não  houve  diferenc¸a
estatística  da  concentrac¸ão  de  TGF-;  entre  pacientes  do  grupo  estudo  que  apresentavam
esofagite  erosiva  em  comparac¸ão  ao  grupo  controle.
Conclusão:  A  concentrac¸ão  salivar  de  TGF-;  foi  estatisticamente  maior  no  grupo  de  indivíduos
com SS  e  RLF,  sem  esofagite  erosiva.
© 2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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Saliva  performs  multiple  roles  in  the  digestive  system
homeostasis.1--6 Examples  of  its  actions  include  the  enzy-
matic  digestion  of  food;  formation  of  the  food  bolus;
facilitation  of  mastication,  swallowing,  and  speech;  lubri-
cation  of  mucous  membranes;  and  maintenance  of  dental
health,  oral  mucosa,  and  the  digestive  system.  Changes
that  interfere  with  the  content  of  saliva  may  therefore
compromise  the  integrity  of  this  delicate  balance  and
generate  consequences  in  the  oral  cavity,  pharynx,  and
esophagus.1,2,4,6,7
More  than  99%  of  saliva  consists  of  water,  with  less  than
1%  solid  elements,  mostly  proteins  and  salts.6 The  inorganic
compounds  of  saliva  are  represented  mainly  by  bicarbon-
ate  ions,  calcium,  and  phosphate.4,5,8--12 In  turn,  the  organic
composition  is  represented  by  a  series  of  proteins  called
growth  factors,  whose  biological  action  is  based  on  the  repli-
cation  and  repair  of  the  epithelium  of  the  digestive  system.13
Due  to  their  inﬂuence  on  the  protective  mechanisms  of  the
digestive  system  during  homeostasis  from  daily  aggressive
factors,  the  most  important  growth  factors  in  saliva  are  the
family  of  epidermal  growth  factors,  which  comprise  epider-
mal  growth  factor  (EGF)  and  also  transforming  growth  factor
--  fraction  alpha  (TGF-).14
b
L
cSalivary  TGF- is  a  potent  mitogenic  50-amino  acid
olypeptide,  whose  healing  properties  are  based  on  its
apacity  to  stimulate  DNA  synthesis  of  epithelial  cells,  with
eoangiogenesis  and  tissue  regeneration  induction  after
ocal  injury.15 The  literature  states  that  salivary  TGF-
xerts  its  inﬂuence  on  the  digestive  system  by  helping
o  maintain  an  appropriate  pre-epithelial  defense  barrier,
hrough  interaction  with  other  salivary  components  such  as
GF,  mucins,  and  salivary  prostaglandins.2,5,6,16
Even  though  the  protective  characteristics  of  TGF- on
he  gastric  mucosa  have  been  demonstrated,5 there  are  no
ata  available  in  the  literature  regarding  the  involvement
f  TGF- in  the  physiopathology  of  supra-esophageal  mani-
estations  of  gastroesophageal  reﬂux  disease  (GERD),  called
aryngopharyngeal  reﬂux  (LPR).
As  it  binds  to  the  same  cell  receptor  as  EGF,  it  can  be
ostulated  that  salivary  TGF- has  a  similar  inﬂuence  as  sali-
ary  EGF  on  laryngeal  protection  against  the  LPR  lesions.17
t  is  known  that  the  biological  effects  of  EGF  include  ulcer
ealing,  gastric  secretion  inhibition,  and  DNA  synthesis  stim-
lation,  in  addition  to  promoting  local  mucosal  protection
gainst  aggressive  factors,  such  as  intraluminal  gastric  acid,
iliary  acids,  pepsin,  and  trypsin.1,2,6 Studies  in  patients  with
PR  observed  deﬁciencies  of  EGF  in  the  salivary  samples
ompared  to  samples  from  healthy  individuals,  suggesting
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 protective  action  of  the  EGF  molecule  on  the  laryngopha-
yngeal  epithelium.9,10,17,18
Another  study  suggested  that  there  would  be  a  primary
alivary  EGF  deﬁciency  in  subjects  with  LPR  that  would
ause  them  to  be  more  likely  to  develop  the  disease,  since
fter  remission  of  symptoms  through  the  treatment  of  LPR,
hese  subjects  had  salivary  EGF  concentration  statistically
imilar  to  concentrations  found  in  the  active  stage  of  the
isease,  and  signiﬁcantly  lower  than  that  found  in  normal
ndividuals.19
Aware  of  the  importance  of  saliva,  Rourk16 and  Korsten20
bserved  that  states  of  hyposalivation  could  increase  the  risk
f  gastroesophageal  reﬂux  disease  (GERD)  by  concomitant
eduction  in  oroesophageal  clearance  and  mucosal  protec-
ion.  Other  authors  have  reported  a  greater  incidence  of
aries  and  periodontitis  in  patients  with  hyposalivation.21--23
As  the  protective  protein  content  is  added  to  the  saliva
t  the  level  of  glandular  acini,  the  search  for  a clinical
xperimental  model  of  hyposalivation  of  acinar  origin  could
ontribute  to  the  understanding  of  the  selective  role  of
alivary  protein  components  in  the  pathogenesis  of  GERD.
ith  this  purpose,  it  was  decided  to  use  Sjögren’s  syn-
rome  (SS)  as  a  clinical  model  for  the  salivary  study,  as  it
epresents  one  of  the  classic  forms  of  known  hyposaliva-
ion,  as  well  as  for  having  an  etiology  related  to  exocrine
cinar  gland  dysfunction  (progressive  lymphoplasmacytic
nﬁltration  and  replacement  of  the  excretory  parenchyma,
articularly  of  the  salivary  glands,  causing  their  failure  and
nducing  hyposalivation).6,24
Previous  studies  have  reported  a  higher  prevalence  of
ERD  and  its  supra-esophageal  manifestations  (LPR)  in  popu-
ations  with  SS,  suggesting  that  the  association  is  a  frequent
ne.5,6,20,25--28 For  Belafsky  and  Postma,25 although  there  is
o  evidence  of  primary  deﬁciencies  in  epithelial  resistance,
he  inﬂammation  of  seromucous  glands  in  patients  with  SS
ake  the  laryngeal,  pharyngeal,  and  esophageal  mucosa
ore  vulnerable  to  the  harmful  effects  of  reﬂuxate.
Based  on  the  above,  the  measurement  of  salivary  TGF-
 levels  in  patients  with  Sjögren’s  syndrome  could  help  to
nderstand  the  mechanism  of  LPR  onset  in  this  population,
ontributing  to  a  better  understanding  of  the  physiopathol-
gy  of  this  disease  and  allowing  the  prevention  of  possible
omplications  that  the  associated  comorbidities  may  cause.
This  study  aimed  to  analyze  the  concentration  of  trans-
orming  growth  factor  --  alpha  subfraction  (TGF-) in  salivary
amples  of  individuals  with  Sjögren’s  syndrome  and  LPR,  and
ompare  them  with  healthy  subjects.
ethods
fter  approval  by  the  Ethics  Committee  on  human  research
f  the  institution  (project  number  354/10),  a  total  of  12
ubjects  with  conﬁrmed  diagnosis  of  Sjögren’s  syndrome  and
1  normal  controls  were  included  in  the  study,  from  August
010  to  February  2013,  in  a  tertiary  university  hospital.
The  diagnosis  of  SS  was  made  according  to  the  deﬁni-
ions  of  the  European-American  consensus  of  2002.29 The
iagnosis  of  LPR  was  made  by  suggestive  laryngopharyngeal
ymptoms  and  a  compatible  video  laryngoscopy,  conﬁrmed
y  upper  digestive  endoscopy  (UDE)  and/or  24-h  dual  chan-
el  esophageal  pH  monitoring  (pH-metry).14,28--31
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All  patients  who  met  the  inclusion  and  exclusion  crite-
ia  were  included  in  the  study,  after  signing  the  informed
onsent  and  receiving  information  on  the  study  objectives,
ethodology,  and  risks.
Inclusion  criteria  were  age  >18  years  and  conﬁrmed
linical,  laboratory,  and  anatomopathological  diagnosis  of
jögren’s  syndrome,  as  well  as  the  agreement  to  undergo
igid  or  ﬂexible  video  laryngoscopy.
The  exclusion  criteria  were  smoking,  alcoholism,  active
nfectious  or  allergic  rhinosinusitis,  and  exposure  to  abra-
ive  chemical  inhalants  and  chronic  lung  diseases,  as  all
hese  factors  cause  inﬂammation  in  the  respiratory  mucosa,
hus  mimicking  the  macroscopic  laryngeal  and  pharyngeal
hanges  found  in  LPR.30,31 In  addition,  patients  unable  to
roduce  sufﬁcient  saliva  volume  for  collection  and  analysis
ere  excluded.  Individuals  using  drugs  known  to  alter  the
ows  of  saliva  and  gastric  secretions,  such  as  diuretics,  anti-
istamines,  proton-pump  inhibitors,  prokinetics,  antacids,
nhaled  asthma  drugs,  neuroleptics,  psychotropics,  and  arti-
cial  saliva  were  also  excluded.32
It  was  also  decided  to  exclude  individuals  undergo-
ng  salivary  gland  and  digestive  system  surgeries,  subjects
ith  pre-neoplastic  and  neoplastic  lesions  of  the  larynx,
harynx,  esophagus,  stomach,  and  duodenum  (present  or
reviously  treated),  and  patients  submitted  to  prior  radio-
herapy  to  prevent  other  possible  methodological  biases.17,33
ll  subjects  were  evaluated  by  the  same  physician,  who
as  experience  in  performing  and  interpreting  laryngoscopy
valuations.
The  control  group  of  11  healthy  female  volunteers  with-
ut  Sjögren’s  syndrome  and  without  GERD  or  LPR  was  also
tudied,  taking  into  account  the  same  abovementioned
xclusion  criteria.
All  individuals  were  submitted  to  anamnesis  and  physi-
al  otorhinolaryngological  examination,  with  measurement
f  weight  and  height  to  calculate  body  mass  index  (BMI,
xpressed  in  kg/m2).  Furthermore,  patients  in  the  study
roup  were  divided  into  two  groups,  according  to  chronic
se  of  drugs  potentially  damaging  to  the  mucosa  of  the
sophagus  and  stomach,  which  may  be  often  used  by  individ-
als  with  SS,  such  as  nonsteroidal  anti-inﬂammatory  drugs,
ethotrexate,  chloroquine,  and  alendronate.  This  informa-
ion  was  used  to  verify  the  inﬂuence  of  the  abuse  of  these
ubstances  with  the  occurrence  of  GERD  and  LPR  in  the  stud-
ed  population.
Subsequently,  the  patients  answered  a  questionnaire
bout  symptoms  suggestive  of  laryngopharyngeal  reﬂux,
alled  the  Reﬂux  Symptom  Index34 (RSI).  A  tool  that  has
een  validated  for  the  English  language,  presently  under-
oing  validation  process  in  Brazil,  the  RSI  is  a  point-based
core  in  which  a  score  >13  indicates  the  presence  of  LPR
ith  95%  accuracy.34
Patients  then  underwent  to  laryngoscopy  with  a  10  mm
nd  70◦ laryngoscope  (model  precision  SN  --  29052;  Storz
- Germany)  coupled  to  a  video  system  (Toshiba,  model
K-CU44A  --  Japan;  LG  DVD  burner,  model  tri-system  --
razil;  and  LG  monitor,  model  tri-system  CineMaster  --
razil).A  ﬂexible  3.4  mm-diameter  nasoﬁbrolaryngoscope  (EPX
200  model  processor  monitor  color  LCD;  Fujinon® --  Japan)
as  used  only  in  cases  of  overactive  gag  reﬂex  or  incapacity
o  visualize  the  laryngopharyngeal  segment  by  telescopy.
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All  examinations  were  recorded  and  stored  on  DVD  media
(LG).  No  topical  anesthetic  was  used  during  the  endoscopic
assessment  of  the  larynx.
The  presence  and  severity  of  signs  suggestive  of  laryn-
gopharyngeal  reﬂux  was  established  by  applying  a  scoring
system  of  endolaryngeal  endoscopic  inﬂammatory  signs
called  Reﬂux  Finding  Score  (RFS),35 or  the  Scale  of  Video-
laryngoscopy  Reﬂux  Findings.36 Similarly  to  the  RSI,34 the
RFS35 has  been  validated  for  the  English  language  and  is
undergoing  validation  in  Brazil.36 According  to  this  tool,  RFS
values  >7  suggest  the  presence  of  LPR  with  95%  accuracy.35,36
To  maintain  the  scientiﬁc  consistency  of  the  project,  in
addition  to  the  use  of  the  two  tools  for  clinical  diagnosis
of  laryngopharyngeal  reﬂux  described  above  (RSI  and  RFS),
patients  underwent  additional  examination  for  evidence  of
GERD  and  LPR  (upper  digestive  endoscopy  --  Fujinon® 2200
series,  9.8  mm  diameter  --  Japan;  and/or  manometry/24-h
dual-channel  esophageal  pH  monitoring;  Alacer  Biomedical
-- São  Paulo,  Brazil).17,30,34,35,37,38 The  presence  of  erosive
esophagitis  in  patients  with  RSI  and  RFS  suggestive  of  reﬂux
conﬁrmed  the  diagnosis  of  GERD/LPR.17,30
Patients  without  endoscopic  conﬁrmation  of  GERD  were
then  subjected  to  24-h  dual  channel  esophageal  pH-metry
preceded  by  esophageal  manometry  to  locate  the  lower
esophageal  sphincter.17,39,40 Proximal  pathological  reﬂux  was
considered  as  any  episode  of  pH  decrease  in  the  proximal
sensor  to  values  <4,  preceded  by  an  event  of  the  same  mag-
nitude  in  the  distal  sensor,  regardless  of  its  duration.37,41 To
determine  the  distal  pathological  reﬂux,  pH  decrease  events
in  the  distal  sensor  demonstrating  levels  <4  were  also  consid-
ered,  following  the  criteria  described  by  Demeester  et  al.42
and  according  to  the  parameters  for  total  acid  exposure  time
deﬁned  by  Jamieson  et  al.43
Cases  with  pH-metry  that  had  proximal  pathological
reﬂux,  isolated  or  associated  with  pathological  distal  reﬂux,
were  considered  positive  for  LPR.17,30,40,44
Salivary  sample  processing  and  analysis
Saliva  collection  was  always  performed  in  the  morning  after
fasting  for  8  h,  in  order  to  comply  with  the  circadian  rhythm
of  salivary  production.  Patients  were  instructed  not  to  brush
their  teeth  or  use  mouthwash  in  the  morning  of  saliva  collec-
tion.  At  the  time  of  collection,  the  patient  was  asked  to  rinse
the  mouth  with  running  water  at  will,  without  swallowing,
to  reduce  excessive  cell  sloughing  present  in  the  oral  cavity.
Two  consecutive  saliva  samples  were  obtained  from  each
participant:  the  ﬁrst,  of  unstimulated  saliva  (called  basal
saliva),  and  the  second  sample,  of  stimulated  saliva,  by
chewing  a  25  cm2 piece  of  paraﬁlm  M® (Pechiney  Plastic
Packing  Chicago,  IL,  USA),  called  stimulated  saliva.5,16,45
Samples  of  basal  and  stimulated  saliva  were  collected  by
asking  the  patient  to  spit  at  will  the  entire  salivary  volume
produced  during  the  period  of  10  min  into  a  universal  bottle
collector.  The  patient  was  instructed  not  to  expectorate  or
spit  nasopharyngeal  secretions  during  the  collection  period,
in  order  to  avoid  contaminating  the  material  with  secretions
that  were  not  salivary.17,18 Moreover,  patients  were  asked
to  remain  silent  during  the  collection  period,  so  as  not  to
interfere  with  salivary  demand.
The  processing  of  saliva  was  carried  out  at  the  same
time  as  collection  by  centrifugation  for  10  min  (3500  rpm
T
S
F465
-  Excelsa  II  centrifuge  --  Fanem;  Brazil)  conditions  neces-
ary  for  sedimentation  of  cell  debris.  The  supernatant  was
eparated  using  pipettes  to  measure  the  volume  and  concen-
ration  of  TGF-, following  the  protocol  established  by
ckley  to  measure  the  concentration  of  salivary  factors.5,30
The  samples  were  then  stored  and  maintained  at  a
emperature  of  −20 ◦C  until  the  time  of  ﬁnal  analysis  of
he  salivary  levels  of  TGF-, which  was  performed  by  the
andwich  ELISA  method  using  the  available  commercial
it  (Quantikine®, R&D  Systems  Inc.  --  United  States).  The
ethod’s  steps  were  performed  according  to  the  manufac-
urer’s  guidelines  described  in  the  instruction  manual.46
A  monoclonal  antibody  speciﬁc  for  TGF- had  been  previ-
usly  adhered  to  the  wells  of  a  microtiter  plate  provided  by
he  manufacturer.  Provided  standard  solutions  and  diluted
ample  solutions  were  pipetted  in  the  wells  and  incubated,
o  that  the  TGF- molecules  would  adhere  to  the  immo-
ilized  antibody  in  the  microtiter  plates.  After  several
ashings,  molecules  that  had  weak  bonds  with  the  speciﬁc
ntibodies  were  removed  and  a  polyclonal  antibody  speciﬁc
or  TGF- respectively  linked  to  an  enzyme  was  added  to  the
olution.  After  further  washings,  a  substrate  for  the  enzyme
ction  was  added,  so  that  color  development  would  occur  in
he  solution,  in  proportion  to  the  amount  of  TGF- respec-
ively  adhered  to  the  wells  at  the  beginning  of  processing.
The  reaction  was  then  interrupted  by  adding  a  spe-
iﬁc  substrate,  and  the  TGF- level  in  each  sample  was
etermined  based  on  the  optical  density  of  the  solu-
ions,  recorded  by  spectrophotometry.  This  concentration
as  established  as  a  function  of  the  overall  concentration
f  salivary  proteins  present  in  the  sample,  regardless  of
he  total  saliva  volume,  by  comparing  optical  densities  of
tandard  solutions  with  previously  known  concentrations  and
xpressed  in  pg/mL.
The  SS  patients  were  subsequently  divided  into  two
roups  according  to  the  severity  of  hyposalivation  and  com-
ared  regarding  salivary  concentrations  of  TGF-. Four
atients  had  mild  hyposalivation  (basal  salivary  volume
etween  1  and  3  mL  and/or  stimulated  salivary  volume
etween  7  and  15  mL),  and  eight  patients  had  severe
yposalivation  (basal  salivary  volume  less  than  1 mL  and/or
timulated  salivary  volume  less  than  7  mL).25,45,47
These  SS  patients  were  further  divided  into  two  other
roups,  according  to  the  presence  of  erosive  esophagitis  at
he  UDE  (present  in  5  cases  and  absent  in  7).  The  two  sub-
roups  were  then  compared  with  each  other  according  to
alivary  levels  of  TGF-.
Statistical  analysis  was  performed  using  the  software
pi  InfoTM 7  (CDC,  Atlanta,  USA)  and  SPSS  --  release  13
or  Windows®.  Summary  measures  for  quantitative  varia-
les  were  calculated.  For  qualitative  variables,  absolute  and
elative  frequencies  were  calculated.  Parametric  and  non-
arametric  statistical  methods  were  used  to  analyze  the
ariables  (Student’s  t-test  and  the  Mann--Whitney  test).  The
evel  of  statistical  signiﬁcance  was  set  at  5%  for  all  analyses.
esultshe  study  group  consisted  of  12  individuals  diagnosed  with
S,  with  a  mean  age  of  56.25  years  ±  8.6,  all  females.
ive  patients  were  diagnosed  with  primary  SS,  and  seven
4 Corvo  MA  et  al.
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Table  1  Levels  of  transforming  growth  factor  alpha  (TGF-
) in  basal  and  stimulated  saliva  samples  after  chewing
paraﬁlm-M  in  the  group  of  patients  with  Sjögren’s  syndrome
and conﬁrmed  laryngopharyngeal  reﬂux  (study  group)  and
the group  of  healthy  volunteers  (control  group).
Salivary  sample  TGF-  (pg/mL)  p-Value
Control  group  Study  group
Basal  saliva  16.2  40.3  0.036
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ith  secondary  SS,  including  four  cases  associated  with  sys-
emic  lupus  erythematosus  (SLE),  two  cases  associated  with
heumatoid  arthritis  (RA),  and  one  case  with  RA  +  SLE  asso-
iation.  To  characterize  the  study  group,  the  mean  time  of
iagnosis  of  Sjögren’s  syndrome  was  also  obtained  at  the
ime  of  study  enrollment.  This  mean  was  5.3  ±  2.2  years.
lso  for  the  study  group,  the  mean  RSI  score  was  22.8  ±  6.56
oints  and  the  RFS  score  was  13.3  ±  1.7  points.
The  control  group  consisted  of  11  healthy  female  vol-
nteers  with  a  mean  age  of  56.1  years  ±  12.7  and  without
ymptoms  of  GERD/LPR  or  videolaryngoscopic  signs  of  LPR.
he  average  RSI  was  4.2  ±  3.8  points  and  the  average  RFS
as  3.4  ±  1.9.
The  diagnosis  of  laryngopharyngeal  reﬂux  was  originally
ttained  in  the  12  subjects  with  Sjögren’s  syndrome  by
pplying  the  RFS  and  RSI  scores  (all  positive  for  LPR).  In
ve  patients,  the  diagnosis  was  later  conﬁrmed  by  UDE  with
rosive  esophagitis,  and  in  seven  subjects  it  was  conﬁrmed
y  the  presence  of  pathological  reﬂux  in  the  proximal  sensor
uring  the  24-h  esophageal  pH  monitoring  with  dual  sensors.
oreover,  eight  of  these  12  analyzed  patients  also  had  the
lassical  form  of  gastroesophageal  reﬂux  disease  (ﬁve  cases
ith  erosive  esophagitis  at  UDE,  as  indicated  above,  associ-
ted  with  three  cases  in  which  the  esophageal  pH  monitoring
howed  concomitant  distal  pathological  reﬂux).
Regarding  BMI,  the  study  group  had  a  mean  of
6.2  ±  4.2  kg/m2,  statistically  similar  to  the  control  group
mean  27.2  ±  4.1  kg/m2)  (Mann--Whitney  test,  p  =  0.806).
Eight  of  the  12  SS  patients  assessed  had  chronic  use  of
otentially  harmful  drugs  to  the  digestive  mucosa.  Never-
heless,  ﬁve  of  these  eight  cases  did  not  show  alterations
uring  the  UDE  (Fisher’s  exact  test,  p  =  1).
There  was  no  statistically  signiﬁcant  difference  between
he  two  groups  regarding  the  age  of  the  studied  subjects
Mann--Whitney  test,  p  =  0.82),  or  regarding  gender  (all  were
omen),  which  made  the  groups  comparable.  In  turn,  con-
rol  and  study  groups  were  statistically  different  when  the
SI  and  RFS  scores  were  analyzed  (ANOVA  p  <  0.001  for  both
ariables).
The  basal  salivary  volume  of  the  study  group
1.6  ±  1.62  mL)  was  signiﬁcantly  lower  than  that  of
he  control  group  (2.6  ±  1.44  mL)  (Mann--Whitney  test,
 =  0.03).  In  addition,  the  stimulated  salivary  volume  in
he  study  group  (6.7  ±  5.54  mL)  was  also  signiﬁcantly  lower
han  in  the  control  group  (9.9  ±  7.29  mL)  (Mann--Whitney
est,  p  =  0.09).
The  concentration  of  TGF- in  the  basal  saliva  was
igniﬁcantly  higher  in  the  study  group  (40.3  pg/mL  ±  40.87)
ompared  to  the  control  group  (16.2  pg/mL  ±  6.59)
Mann--Whitney  test,  p  =  0.036).  The  same  was  observed
n  the  concentrations  of  TGF- in  stimulated  saliva  in  the
tudy  group  (21.0  pg/mL  ±  20.83)  compared  to  the  control
roup  (11.0  pg/mL  ±  1.92)  (Mann--Whitney  test,  p  =  0.015)
Table  1).
When  comparing  the  control  group  separately  with  the
ve  cases  with  erosive  esophagitis,  it  was  observed  that  the
ean  TGF- levels  in  basal  and  stimulated  saliva  of  the  study
roup  with  erosive  esophagitis  (31.2  and  11.8  pg/mL,  respec-
ively)  were  statistically  similar  to  those  of  the  control
roup  (16.2  and  11.0  pg/mL,  respectively)  (Mann--Whitney
est,  p  =  0.395  for  basal  saliva  and  p  =  0.335  for  stimulated
aliva).
l
e
aStimulated  saliva  11.0  21.0  0.015
TGF-, transforming growth factor alpha.
However,  when  comparing  the  control  group  separately
ith  the  seven  cases  without  erosive  esophagitis,  it  was
bserved  that  the  mean  TGF- levels  in  basal  and  stimu-
ated  saliva  of  the  study  group  without  erosive  esophagitis
46.7  and  23.5  pg/mL)  were  statistically  higher  than  those
f  the  control  group  (16.2  and  11.0  pg/mL)  (Mann--Whitney
est,  p  =  0.016  for  baseline  saliva  and  p  =  0.005  for  stimulated
aliva).
In the  group  with  mild  hyposalivation,  the  mean  level
f  TGF- in  saliva  at  baseline  was  13.5  ±  3.34  pg/mL,  while
n  the  stimulated  saliva  it  was  11.4  ±  1.84  pg/mL.  When
nalyzing  the  group  with  severe  hyposalivation,  the  values
f  TGF- found  in  the  basal  and  stimulated  samples  were
3.7  ±  44.8  and  25.7  ±  24.5  pg/mL,  respectively.
The  salivary  level  of  TGF- in  the  group  with
evere  hyposalivation  was  statistically  higher  in  the  basal
Mann--Whitney  test,  p  =  0.007)  and  stimulated  samples
Mann--Whitney  test,  p  =  0.089),  when  compared  to  the
roup  with  mild  hyposalivation.
iscussion
he  high  prevalence  of  GERD  and  LPR  in  subjects  with  SS
ad  already  been  described  by  the  current  research  group
n  an  article  published  in  2012.30 At  that  time,  the  presence
f  LPR  was  observed  in  100%  of  individuals  in  a  group  of  19
dults  with  SS.30 The  sample  used  in  this  study  was  new  and
ncluded  12  new  subjects  with  SS,  all  of  whom  had  LPR  (eight
f  whom  also  had  GERD),  conﬁrming  the  high  frequency  of
he  association  in  subpopulations  with  SS.
In  the  present  study,  the  presence  of  GERD  was  not  inﬂu-
nced  by  BMI,  nor  by  chronic  use  of  medications  that  are
otentially  harmful  to  the  mucosa  of  the  esophagus  and
tomach,  suggesting  that  GERD  in  patients  with  SS  is  appar-
ntly  not  inﬂuenced  by  the  same  risk  factors  classically
ssociated  with  GERD  in  the  general  population  without
erostomia.
The  assessment  of  TGF- levels  in  saliva  was  motivated
y  the  recognized  importance  of  this  growth  factor  on  the
igestive  system  homeostasis,  both  through  its  healing  and
eoangiogenesis-inducing  effects,  as  well  as  by  its  inhibitory
ction  against  gastric  secretion.5,14,48
Moreover,  there  are  no  data  in  the  literature  analyzing
he  levels  of  salivary  TGF- in  individuals  with  LPR,  much
ess  comparing  this  information  in  a  population  consisting
xclusively  of  patients  with  SS.
It  is  known  that  the  protein  content  is  added  to  the  saliva
t  the  level  of  the  salivary  gland  acini.6,49 However,  it  is
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unclear  whether  there  would  be  a  difference  in  the  rate
of  salivary  excretion  of  TGF- according  to  the  type  of  sali-
vary  gland  assessed.  The  exclusive  analysis  of  baseline  saliva
would  mainly  evaluate  the  contribution  of  submandibular
glands  to  the  overall  content,  while  stimulated  samples
would  reﬂect  greater  parotid  contribution.6 Thus,  it  was
decided  to  collect  basal  and  stimulated  saliva  samples  to
obtain  better  representation  of  the  overall  saliva  produc-
tion.
Regarding  the  results  obtained,  in  fact,  the  salivary  level
of  TGF- in  subjects  with  SS  was  signiﬁcantly  higher  than
that  in  the  control  group,  both  in  basal  and  stimulated  sali-
vary  samples.
Given  that  the  essential  role  of  TGF- is  to  stimulate
tissue  healing,  the  ﬁndings  of  its  increased  salivary  con-
centrations  in  subjects  with  SS  and  LPR  suggest  that  this
growth  factor  may  participate  in  the  ﬁrst  line  of  defense  in
the  body’s  response  to  aggression  resulting  from  GERD/LPR,
also  suggesting  that  its  local  production  plays  a  signiﬁcant
role  in  the  reconstitution  of  the  laryngeal  and  pharyngeal
mucosa  in  post-injury  repair.
No  publications  were  found  that  assessed  the  salivary
concentrations  of  TGF- and  their  possible  involvement  in
the  genesis  of  supraesophageal  manifestations  of  GERD.
However,  when  analyzing  the  few  studies  on  the  par-
ticipation  of  this  growth  factor  in  the  homeostasis  of  the
digestive  system,  the  results  observed  in  this  analysis  agree
with  those  published  by  Polk  et  al.,  who  reported  an
increase  in  the  production  of  TGF- in  response  to  acute
gastric  aggression  with  HCl.50 Similar  ﬁnding  was  observed
by  Fujiwara  et  al.,  when  analyzing  mice  with  chronic
reﬂux  esophagitis.15 According  to  these  authors,  activa-
tion  of  TGF- in  response  to  pathological  esophageal  reﬂux
could  facilitate  mucosal  healing  by  stimulating  epithelial
proliferation.15
In  the  current  study,  when  the  group  of  individuals  with
SS  were  subdivided  according  to  the  degree  of  hyposaliva-
tion,  the  objective  was  to  analyze  the  inﬂuence  of  the  most
advanced  stages  of  acinar  dysfunction  on  the  capacity  of
TGF-  salivary  production  and,  consequently,  on  the  defense
capacity  of  the  laryngopharyngeal  and  digestive  mucosa.
Subjects  with  severe  hyposalivation  showed  higher  con-
centrations  of  TGF-, reinforcing  that  this  growth  factor
participates  in  a  compensatory  defense  mechanism.  Thus,
more  advanced  stages  of  salivary  dysfunction  would  quali-
tatively  try  to  meet  the  quantitative  deﬁciency  of  salivary
volume  produced  by  the  individual.
Considering  only  patients  in  the  study  group  with  LPR  who
had  erosive  esophagitis,  no  differences  were  observed  in
basal  and  stimulated  salivary  concentrations  of  TGF- when
compared  to  the  control  group.  Furthermore,  the  subgroup
without  esophagitis  responded  to  aggression  with  a  signiﬁ-
cantly  higher  level  of  TGF- in  basal  and  stimulated  samples,
when  compared  to  the  control  group.
Assuming  that  the  presence  of  erosive  esophagitis  at
UDE  constitutes  a  complication  of  more  severe  GERD/LPR,
the  abovementioned  facts  suggest  that  the  subgroup  with
esophagitis  would  have  an  intrinsic  difﬁculty  in  increasing
the  production  and/or  secretion  of  salivary  TGF-, neces-
sary  to  prevent  the  emergence  of  this  complication.  It  is
assumed,  then,  that  the  capacity  of  the  studied  subjects
with  SS  to  respond  to  the  aggression  of  GERD/LPR  with  higher467
alivary  level  of  TGF- would  have  prevented  the  onset  of
rosive  esophagitis  in  this  study.
Thus,  it  is  possible  to  hypothesize  that  the  response  of
n  individual  with  xerostomia  to  the  presence  of  GERD/LPR
ould  be  the  increase  in  salivary  TGF-, as  a  compensatory
ffect  to  prevent  disease  progression.  Cases  with  an  insuf-
cient  increase  would  have  complications,  such  as  erosive
sophagitis.
In  the  sample  analyzed  over  a  period  of  three  years,  there
ere  no  SS  patients  without  GERD/LPR.  It  is  postulated  that
he  measurement  of  salivary  TGF- levels  in  a  subgroup  of
S  patients  without  GERD/LPR  and  their  comparison  with  a
roup  of  SS  patients  with  GERD/LPR  can  be  enlightening  to
isclose  the  participation  of  this  salivary  factor  in  the  bio-
hemical  balance  of  the  digestive  system.  Given  the  rarity
f  SS,  multicenter  studies  have  been  shown  to  be  necessary
o  increase  the  representativeness  of  the  ﬁndings  and  prove
he  scientiﬁc  hypotheses.
If  conﬁrmed  in  future  studies,  the  results  may  poten-
ially  have  signiﬁcant  clinical  relevance  in  the  management
f  patients  with  SS.  Can  the  measurement  of  salivary  con-
entrations  of  TGF- predict  groups  of  subjects  with  SS  that
ould  present  more  severe  forms  of  GERD/LPR,  and  thus,
ould  require  more  intensive  care?
These  ﬁndings  call  attention  to  the  fact  that  the  etiology
f  supraesophageal  manifestations  of  GERD  is  yet  to  be  fully
nderstood,  especially  when  considered  in  such  a  unique
roup  of  individuals  with  SS.
onclusion
n  the  present  study,  the  level  of  TGF- was  statistically
igher  in  the  basal  and  stimulated  salivary  samples  of
ndividuals  with  Sjögren’s  syndrome  and  laryngopharyngeal
eﬂux,  when  compared  to  the  respective  samples  from
ealthy  controls.
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